Commentary
Video
Dr. Tyson shares interim findings from the BOND-003 trial in NMIBC
Author(s):
Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.
Video Player is loading.
In this video, Mark D. Tyson, II, MD, MPH, shares the background and key findings from the study, “BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer,” which was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Tyson is a urologic oncologist at Mayo Clinic in Phoenix, Arizona.
Related Videos
Joseph Jacob, MD, on the high CR rate with TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Jason Hafron, MD, outlines AUA 2025 session on clinical trial recruitment
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Related Content
